[Dilemma between gastroprotection and cardiovascular prevention]

Area of Science:

• Pharmacology
• Gastroenterology
• Cardiology

Background:

• Low-dose aspirin and clopidogrel increase upper gastrointestinal (GI) bleeding risk.
• Proton pump inhibitors (PPIs) are used for gastric protection in patients on antiplatelet therapy.
• A potential interaction between PPIs and clopidogrel raises concerns about reduced clopidogrel efficacy.

Purpose of the Study:

• To review literature on PPI use for gastric protection in patients on antiplatelet therapy.
• To focus on the potential interaction between clopidogrel and PPIs.
• To evaluate the impact of PPIs on clopidogrel's efficacy.

Main Methods:

• Selected literature review.
• Analysis of ex vivo platelet function studies.
• Evaluation of in vivo evidence regarding clopidogrel-PPI interaction.

Main Results:

• Ex vivo studies showed reduced clopidogrel efficacy with omeprazole, but not other PPIs.
• No clear in vivo evidence currently exists to confirm PPIs reduce clopidogrel efficacy.
• A split-dosage regimen (PPI in morning, clopidogrel in evening) is suggested if co-prescription is necessary.

Conclusions:

• The interaction between clopidogrel and PPIs requires careful consideration.
• Current evidence does not definitively prove that PPIs compromise clopidogrel efficacy in vivo.
• A split-dosage regimen may mitigate potential risks associated with concomitant clopidogrel and PPI use.